Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.supriyalifescience.com | |
Market Cap | 1,614.48 Cr. | |
Enterprise Value(EV) | 1,455.35 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 15.90 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 12.62 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.44 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 81.00 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 2.48 | Calculated using Price: 200.60 |
Dividend Yield | 0.30 | Period Ending 2022-03 |
No. of Shares Subscribed | 8.05 Cr. | 80,482,800 Shares |
FaceValue | 2 | |
Company Profile | ||
The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development. The company has niche product offerings of various APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic. |
1 Day |
|
-1.67% |
1 Week |
|
-6.59% |
1 Month |
|
-15.61% |
3 Month |
|
-29.36% |
6 Month |
|
-46.23% |
1 Year |
|
-57.97% |
2 Year |
|
|
5 Year |
|
|
10 Year |
|
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 29.57 | 29.61 | 17.20 | 15.05 | 18.38 | 53.11 | 60.42 | 59.17 | 34.34 | |
Return on Capital Employed (%) | 19.43 | 15.83 | 12.27 | 11.48 | 13.80 | 36.52 | 49.67 | 60.12 | 43.34 | |
Return on Assets (%) | 5.42 | 5.37 | 2.80 | 2.40 | 3.59 | 15.82 | 24.90 | 31.61 | 25.73 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 30 | 37 | 42 | 46 | 55 | 94 | 149 | 269 | 616 | 652 | |
Non Curr. Liab. | 17 | 23 | 39 | 51 | 45 | 24 | 32 | 31 | 19 | 21 | |
Curr. Liab. | 83 | 115 | 150 | 144 | 146 | 135 | 155 | 146 | 100 | 89 | |
Minority Int. | |||||||||||
Equity & Liab. | 130 | 176 | 231 | 241 | 245 | 253 | 336 | 445 | 735 | 762 | |
Non Curr. Assets | 52 | 73 | 102 | 126 | 126 | 120 | 138 | 180 | 237 | 268 | |
Curr. Assets | 78 | 103 | 129 | 115 | 120 | 133 | 198 | 265 | 498 | 494 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 130 | 176 | 231 | 241 | 245 | 253 | 336 | 445 | 735 | 762 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 113 | 138 | 171 | 184 | 213 | 278 | 312 | 391 | 530 | 512 | |
Other Income | 2 | 2 | 2 | 7 | 9 | 8 | 11 | 5 | 8 | 14 | |
Total Income | 115 | 140 | 173 | 191 | 222 | 286 | 323 | 396 | 538 | 526 | |
Total Expenditure | -98 | -121 | -151 | -166 | -191 | -213 | -213 | -218 | -316 | -315 | |
PBIDT | 16 | 20 | 22 | 25 | 31 | 73 | 109 | 178 | 222 | 211 | |
Interest | -6 | -7 | -10 | -12 | -11 | -10 | -7 | -4 | -4 | -27 | |
Depreciation | -2 | -2 | -4 | -5 | -5 | -5 | -6 | -7 | -10 | -11 | |
Taxation | -2 | -2 | -2 | -2 | -6 | -18 | -23 | -44 | -55 | -45 | |
Exceptional Items | |||||||||||
PAT | 6 | 8 | 6 | 6 | 9 | 39 | 73 | 124 | 152 | 128 | |
Adjusted EPS | 13 | 17 | 4 | 4 | 6 | 27 | 50 | 17 | 19 | 16 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | -6 | 14 | 27 | 28 | 49 | 116 | 76 | 49 | |||
Cash Fr. Inv. | -23 | -33 | -27 | -5 | 5 | -25 | -47 | -60 | |||
Cash Fr. Finan. | 30 | 21 | -2 | -20 | -50 | -29 | -15 | 150 | |||
Net Change | 1 | 2 | -2 | 3 | 4 | 62 | 15 | 139 | |||
Cash & Cash Eqvt | 5 | 7 | 6 | 9 | 12 | 75 | 89 | 228 |
Mon, 23 Jan 2023
Appointment Of Chief Financial Officer & Key Managerial Personnel Appointment of Mr. Krishna Raghunathan as the Chief Financial Officer (KMP) of the Company with effect from January 23 2023. Mr. Krishna Raghunathan is a dynamic professional with 23+ years of rich experience in financial management. In his last role Mr. Raghunathan worked for ~5 years as Vice President - Finance Treasury and Investor Relations with a listed pharmaceuticals Company. Mr. Raghunathan has a demonstrated history of working in diverse industries including pharmaceuticals packaging and information technology. Mr. Raghunathan is a seasoned pharma specialist with more than 2 decades of experience in companies like Dr. Reddys Laboratories Limited and Granules India Limited. His appointment is in line with companys strategy to achieve accelerated growth in the years to come. |
Mon, 23 Jan 2023
Announcement under Regulation 30 (LODR)-Resignation of Director Pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 it is hereby informed that Mr. Balasaheb Sawant Whole Time Director and Key Managerial Personnel of the Company has tendered his resignation with effect from January 23 2023 due to the personal reason. |
Mon, 23 Jan 2023
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) With reference to the captioned subject and pursuant to regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Board of Directors has approved the following change(s) in Key Managerial Personnel (Chief Financial Officer) of the Company at their meeting held today i.e. January 23 2023.Mr. Ashish Nayak has resigned from the position of Chief Financial Officer & KMP of the Company and the Board has accepted his resignation with effect from close of business hours on January 23 2023 however he will be relieved from the company on January 31 2023 for smooth transition to his successor. |
Thu, 02 Feb 2023 |
|
|
|
|
|